miv-cel BLA Advances on Qualitative Data Alone: Durability Claim Unverified, gMG Evidence Tier Insufficient

Kyverna's Miv-cel Shows Durable Efficacy and Safety in SPS and gMG

Kyverna Therapeutics announced positive one-year topline data from its registrational KYSA-8 trial of miv-cel in Stiff Person Syndrome (SPS) and longer-term follow-up data from the Phase 2 portion of its KYSA-6 trial in generalized myasthenia gravis (gMG). The data demonstrated durable clinical responses and a consistently favorable safety profile for miv-cel, a CD19-targeting CAR T-cell therapy. These results reinforce miv-cel's potential as a transformative, single-dose therapy for neurologic autoimmune diseases and support the ongoing rolling Biologics License Application (BLA) submission for SPS, expected to be completed in Q4 2026.

• In the KYSA-8 SPS trial (n=26), miv-cel demonstrated significant and sustained improvements in the timed 25-Foot Walk (T25FW) at 12 months (median 49% improvement from baseline, p < 0.0001). 95% of patients who achieved a clinically meaningful improvement at primary analysis sustained their benefit, and 67% of those requiring a walking aid prior to treatment no longer needed assistance.
• For the KYSA-6 Phase 2 gMG trial (n=7), a single dose of miv-cel led to deep and durable clinical responses. All 7 patients achieved clinically meaningful improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) at 24 weeks (mean reductions of -8.3 and -11.7 points, respectively), with these improvements maintained through one year or longer in all five patients who reached this time point.
• Miv-cel maintained a consistent and well-tolerated safety profile across both trials, with no high-grade cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), or immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS). The positive one-year SPS data will be included in the rolling BLA submission, which is on track for completion in Q4 2026.

The Unmet Need in Stiff Person Syndrome and Generalized Myasthenia Gravis

Current treatment approaches for SPS are constrained by a narrow therapeutic window, significant tolerability issues, and the absence of robust clinical trial evidence supporting any single regimen. The rarity of the condition — affecting only 1–2 people per million — compounds these challenges, limiting the scale of prospective research and leaving clinicians reliant on case series and expert consensus.

• Adverse effects frequently limit standard pharmacotherapy. GABAergic agents such as diazepam, clonazepam, baclofen, and gabapentin form the backbone of symptomatic management, yet adverse effects can preclude their introduction or prevent dose escalation. In documented cases, patients have been unable to tolerate clonazepam and baclofen, and could not have doses of diazepam, gabapentin, or levetiracetam increased due to adverse effects — leaving acute exacerbations inadequately controlled.

• Immunomodulatory therapies carry their own tolerability and efficacy limitations. Corticosteroids, a common immunotherapy option, can precipitate serious complications; methylprednisolone has been associated with severe hyperglycemia in SPS patients. Rituximab has been evaluated in random clinical trials, but "nothing concrete has been suggested," and evidence of efficacy across immunomodulatory agents remains limited to case series, with large prospective randomized controlled trials lacking.

• Refractory cases represent a distinct and underserved population. Standard treatments — including high-dose benzodiazepines, baclofen, and intravenous methocarbamol — can fail to provide adequate relief in severe exacerbations, necessitating investigational approaches such as intravenous ketamine or therapeutic plasma exchange (TPE) as adjunct therapies. TPE has demonstrated a good safety profile in exacerbations unresponsive to medical therapy, but its role remains adjunctive rather than disease-modifying.

• Emerging therapies such as CAR T-cell therapy remain early-stage. CD19 CAR T cells have shown promising benefits in case series of SPS patients with disease "refractory to all available therapies, including rituximab and new biologics," with some patients exhibiting "impressive clinical improvements with long-lasting benefits." However, this evidence base is nascent, and the preparation, administration, and safety profile of CAR T cells in autoimmune settings present distinct challenges compared to their oncologic use.

• Comorbid autoimmune conditions complicate management. SPS frequently co-occurs with type 1 diabetes, autoimmune thyroid disease, and other GAD antibody-associated disorders, introducing additional therapeutic complexity. The "clinical heterogeneity implies variable susceptibility of γ-aminobutyric acid-ergic neurons and pancreatic beta cells to anti-GAD or other autoantibodies," making standardized treatment protocols difficult to apply across the patient population.

Miv-cel's Durable Efficacy and Favorable Safety in SPS and gMG

Recent clinical investigations into Stiff Person Syndrome have evaluated a range of immunomodulatory and neuromodulatory interventions, reflecting the heterogeneity of treatment approaches in this rare autoimmune disorder. The studies below highlight key efficacy and safety findings across controlled trials and case-based evidence.

Miv-cel's Breakthrough: Reshaping Neuroautoimmune Treatment

The recent positive one-year data for miv-cel in Stiff Person Syndrome (SPS) and longer-term follow-up in generalized myasthenia gravis (gMG) mark a pivotal moment for the application of CAR T-cell therapy. Historically confined to hematologic malignancies, this fully human anti-CD19 CAR T-cell therapy is demonstrating its potential to profoundly impact chronic, debilitating neuroimmunological autoimmune diseases. The observed durable clinical responses, coupled with a consistently favorable safety profile, suggest that miv-cel could offer a transformative, single-dose treatment option for patients who often have limited or ineffective therapeutic alternatives.

This expansion into autoimmune indications is underpinned by several key factors. Research indicates that CD19 CAR T-cells can penetrate the central nervous system, as seen in studies involving multiple sclerosis patients, without inducing severe neurotoxicity like ICANS, which is a critical safety consideration for neurological conditions. Furthermore, the manufacturing process for KYV-101 has proven robust, successfully generating viable and functional CAR T-cell products from patients across diverse autoimmune disease types, regardless of their prior treatment history. This manufacturing consistency, including the ability to cryopreserve apheresis and the final drug product, is essential for scalable production and broad distribution.

However, as with any groundbreaking therapy, important considerations remain. While initial safety data are encouraging, larger controlled trials are necessary to fully characterize the long-term safety profile across a more heterogeneous patient population. The sustained durability of B-cell depletion and clinical benefit beyond the current follow-up periods will also be crucial to confirm miv-cel's long-term value. Finally, the inherent complexities and high costs associated with CAR T-cell therapies present significant hurdles for widespread patient access and reimbursement, requiring strategic planning for market integration. Despite these challenges, the compelling clinical data position miv-cel to potentially redefine treatment paradigms for severe autoimmune diseases, offering a new frontier in precision medicine.